BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces Reverse Stock Split

06 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Provides Clinical and Business Update

05 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

22 Nov 2024 08:16:40 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering

21 Nov 2024 16:47:12 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

14 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

08 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at ThinkEquity Conference

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

19 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

21 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire